転移性卵巣がん(Metastatic Ovarian Cancer)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Metastatic Ovarian Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Metastatic Ovarian Cancer – Overview 8
Pipeline Products for Metastatic Ovarian Cancer – Comparative Analysis 9
Metastatic Ovarian Cancer – Therapeutics under Development by Companies 10
Metastatic Ovarian Cancer – Therapeutics under Investigation by Universities/Institutes 11
Metastatic Ovarian Cancer – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Metastatic Ovarian Cancer – Products under Development by Companies 14
Metastatic Ovarian Cancer – Products under Investigation by Universities/Institutes 15
Metastatic Ovarian Cancer – Companies Involved in Therapeutics Development 16
Aura Biosciences, Inc. 16
Eisai Co., Ltd. 17
Immune Design Corp. 18
Innate Pharma SA 19
Millennium Pharmaceuticals, Inc. 20
Northwest Biotherapeutics, Inc. 21
Sumitomo Dainippon Pharma Co., Ltd. 22
VG Life Sciences, Inc. 23
Metastatic Ovarian Cancer – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
antigen-presenting dendritic cells (living, autologous) – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DCVax-Direct – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drugs for Cancer – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drugs for Metastatic Ovarian Cancer – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
E-7449 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
G-305 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
hydroxychloroquine + sorafenib tosylate – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
IPH-2201 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LV-305 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
orteronel – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SM-276001 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Stem Cell Therapy for Oncology – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Metastatic Ovarian Cancer – Recent Pipeline Updates 50
Metastatic Ovarian Cancer – Dormant Projects 62
Metastatic Ovarian Cancer – Discontinued Products 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65